SARM1 Protein Detects Foreign DNA and Destroys NAD+ to Kill Cells
Scientists discover SARM1 acts as a DNA sensor, triggering NAD+ depletion and cell death — with major implications for neuropathy treatment.
Summary
Researchers have identified a surprising new role for SARM1, a protein best known for driving neuron death: it directly senses double-stranded DNA (dsDNA) and responds by degrading NAD+, a molecule critical for cellular energy and longevity. When cytosolic dsDNA — whether from lab transfection or chemotherapy drugs — binds to SARM1's TIR domain, the protein activates and depletes NAD+, ultimately killing the cell. Crucially, knocking out SARM1 in mice blocked chemotherapy-induced neuropathy, a debilitating side effect affecting many cancer patients. This positions SARM1 as a novel DNA sensor and a promising therapeutic target for protecting neurons during cancer treatment.
Detailed Summary
Understanding how cells detect foreign or damaged DNA is central to biology and medicine. While sensors like cGAS-STING are well established, researchers continue to uncover new DNA-detection pathways. This study, published in Cell, reveals that SARM1 — previously known mainly as a pro-degenerative executioner in neurons — functions as a direct double-stranded DNA (dsDNA) sensor.
The research team demonstrated that dsDNA binds directly to SARM1's TIR (Toll/interleukin-1 receptor) domain in a sequence-independent manner, meaning any dsDNA can trigger activation regardless of its genetic content. Specific lysine residues within the TIR domain are responsible for this binding interaction.
In cellular experiments, cytosolic dsDNA — introduced either by transfection or chemotherapy agents — colocalized with SARM1, activating its NADase enzymatic activity and driving rapid NAD+ degradation. Since NAD+ is essential for cellular metabolism, DNA repair, and sirtuins (key longevity proteins), its depletion leads swiftly to cell death. Both SARM1 knockout and mutation of its DNA-binding residues abolished this effect.
In mouse models, SARM1 knockout significantly blocked chemotherapy-induced peripheral neuropathy (CIN), one of the most common and dose-limiting toxicities of cancer treatment. This strongly suggests that SARM1-mediated NAD+ destruction is a key mechanism underlying nerve damage from chemotherapy drugs.
For longevity researchers, this finding is significant: NAD+ decline is a hallmark of aging, and SARM1-driven NAD+ degradation in response to cellular stress or DNA damage could accelerate aging-related neurodegeneration. Targeting SARM1 pharmacologically may offer a dual benefit — protecting neurons during chemotherapy and potentially slowing NAD+ decline in aging tissues. Caveats include the study's focus on cancer and neuropathy contexts, with limited direct aging data.
Key Findings
- SARM1 directly binds dsDNA via its TIR domain in a sequence-independent manner, acting as a novel DNA sensor.
- dsDNA activation of SARM1 triggers NAD+ degradation and subsequent cell death in vitro.
- Chemotherapy-induced cytosolic dsDNA activates SARM1, linking DNA damage to NAD+ depletion.
- SARM1 knockout in mice significantly blocked chemotherapy-induced peripheral neuropathy.
- Lysine residues in the TIR domain are critical for dsDNA binding and SARM1 activation.
Methodology
The study combined biochemical binding assays, cellular colocalization experiments, SARM1 knockout models, and point mutation analysis to establish dsDNA sensing. Mouse models of chemotherapy-induced neuropathy were used to validate in vivo relevance. Both transfected dsDNA and chemotherapy-generated cytosolic DNA were tested as activating stimuli.
Study Limitations
The study was conducted primarily in cancer cell lines and mouse neuropathy models, so direct implications for normal aging require further investigation. The sequence-independent nature of dsDNA sensing raises questions about how SARM1 avoids inappropriate activation under physiological conditions. Long-term effects of SARM1 inhibition on immune defense and genomic surveillance are not addressed.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.